Key result
The presence of type II diabetes mellitus did not significantly affect the prevalence of aspirin resistance compared to non-diabetic patients (41.9% vs 43.2%; RR 0.95).
Why the study?
Does the presence of type II diabetes mellitus increase the prevalence of aspirin resistance compared to non-diabetic patients?
Population
130 participants, comprising 93 patients with type II diabetes mellitus and 37 non-diabetic controls
Comparison
Aspirin therapy vs Non-diabetic patients
Design
Cross-sectional
Authors
Loading...
Type 2 diabetes does not appear to increase aspirin resistance prevalence; leaves open hypercholesterolemia as a predictor in diabetics.
Cross-Sectional (n=130)
No
Does the presence of type II diabetes mellitus increase the prevalence of aspirin resistance compared to non-diabetic patients?
Relative Risk: 0.95 (95% CI 0.44–2.05)
Absolute Event Rate: 41.9% vs 43.2%
p-value: p=0.89
The prevalence of aspirin resistance is similar between diabetic and non-diabetic patients, though hypercholesterolemia is an independent predictor of resistance in those with diabetes.
Taşdemir et al. (2013) conducted a cross-sectional in Type II diabetes mellitus (n=130). Type II diabetes mellitus vs. Non-diabetic patients was evaluated on Prevalence of aspirin resistance (RR 0.95, 95% CI 0.44-2.05, p=0.89). The presence of type II diabetes mellitus did not significantly affect the prevalence of aspirin resistance compared to non-diabetic patients (41.9% vs 43.2%; RR 0.95).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: